表皮生长因子受体1蛋白表达与乳腺癌分子分型及激素受体状态的关系

Expression of EGFR in breast cancer and its correlation to molecular subtyping and hormone receptor status

目的探讨表皮生长因子受体1（epidermal growth factor receptor1，EGFR）蛋白表达与乳腺癌分子分型及激素受体表达状态之间的关系。方法选取乳腺癌病例467例。根据ER、PR、HER2和Ki67表达状态将病例分成4个分子亚型，其中Luminal A 185例、Luminal B 109例、HER2过表达型76例、三阴性乳腺癌（triple—negative breast cancer，TNBC）70例。根据ER和PR表达状态将病例分成4个组别，其中ER＋／PR＋240例、ER＋／PR-50例、ER-／PR＋4例、ER-／PR-173例。采用免疫组织化学EnVision法检测各组肿瘤组织中EGFR蛋白的表达。结果@LuminalA、LuminalB、HER2过表达型、TNBC组织中EGFR蛋白阳性率分别为16．8％（31／185）、54．1％（59／109）、97．4％（74／76）、78．6％（55／70）。HER2过表达型的EGFR蛋白表达率显著高于TNBC、LuminalB和LuminalA（均P〈0．01）；TNBC中EGFR蛋白表达率显著高于LuminalB和LuminalA（均P〈0．01）；LuminalB中EGFR蛋白表达率显著高于LuminalA（P〈0．01）。@ER＋／PR＋组、ER＋／PR-组、ER-／PR＋组、ER-，PR-组中EGFR蛋白阳性率分别为25．4％（61／240）、52．0％（26／50）、75．0％（3／4）、88．4％（153／173）。ER-／PR-组中EGFR蛋白阳性率显著高于ER＋／PR＋组和ER＋／PR-组（均P〈0．01），且较ER-／PR＋组高，但差异无统计学意义（P〉0．05）；ER-／PR＋组中EGFR蛋白阳性率较ER＋／PR＋组和ER＋／PR-组高，但差异无统计学意义（P〉0．05）；ER＋／PR-组中EGFR蛋白阳性率显著高于ER＋／PR＋组（P〈0．01）。结论EGFR蛋白表达与乳腺癌分子分型及激素受体阴性表达密切相关，是一个潜在的抗乳腺癌治疗生物标志物。

Objective To study the expression of epidermal growth factor receptor 1 （EGFR） protein in breast cancer and its correlation to molecular subtyping and hormone receptor status. Methods 467 cases of breast cancer were included. According to ER, PR, HER2, and Ki-67 status, the cases were categorized into 4 molecular subtypes, including 185 cases of luminal A, 109 cases of luminal B, 76 cases of HER2-enriched, and 70 cases of triple-negative breast cancer （TNBC）. According to ER and PR status, the cases were divided into 4 subtypes, including 240 cases of ER＋/PR＋, 50 cases of ER＋/PR-, 4 cases of ER-/PR＋, and 173 cases of ER-/PR-.Results EGFR protein expression rates in Luminal A, Luminal B, HER2-enriched and TNBC were 16.8% （31/ 185）, 54.1% （59/109）, 97.4% （74/76）, 78.6%（55/70）, respectively. The EGFR expression in HER2-enriched was significantly higher than those in TNBC, Luminal B and Luminal A（P〈0.01 ）, and EGFR expression in TNBC was significantly higher than those in Luminal B and Luminal A （P〈0.01）, furthermore, EGFR expression in Luminal B was significantly higher than that in Luminal A （P〈0.01）. EGFR protein expression rates in ER＋/PR＋ subtype, ER＋/PR- subtype, ER-/PR＋ subtype and ER-/PR- subtype were 25.4% （61/240）, 52.0% （26/50）, 75.0% （3/4）, 88.4% （153/173）, respectively. The EGFR expression in ER-/PR- subtype was significantly higher than in ER＋/ PR＋ subtype and ER＋/PR- subtype （P〈0.01）, and EGFR expression in ER＋/PR- subtype was significantly higher than that in ER＋/PR＋ subtype （P〈0.01）. EGFR protein expression rate was higher in ER-/PR- subtype than in ER-/PR ＋ subtype, and EGFR protein expression rate was higher in ER-/PR＋ subtype than that in ER＋/PR ＋ subtype and ER＋/PR- subtype, but all of the difference were not statistically significant （P〉0.05）. Conclusion EGFR protein expression is closely related to breast cancer molecular subtyping and negative hormone receptor expression, which is a potential biomarker of anti-breast cancer therapy.